HIV and Heart Disease: Understanding the Connection

For years, HIV infection was considered primarily an immunological disease. However, advances in antiretroviral therapy (ART) have dramatically increased the lifespan of individuals living with HIV, leading to a growing recognition of cardiovascular disease (CVD) as a significant health concern within this population. While ART has been transformative, it hasn’t eliminated the increased risk of heart problems for people with HIV. This article explores the complex relationship between HIV and cardiovascular health, examining the underlying causes, current understanding and future directions for research.

The Rising Prevalence of Cardiovascular Disease in People with HIV

Cardiac involvement is increasingly common in individuals with HIV, with prevalence rates ranging from 28% to 73% ¹. Before the widespread use of ART, HIV-associated CVD often manifested as HIV-associated cardiomyopathy, linked to severe immune deficiency. Now, with effective viral suppression and immune restoration through ART, the effects of HIV on the cardiovascular system are more subtle, yet still significant. People living with HIV continue to face a higher incidence of cardiovascular pathology.

How HIV Impacts the Heart

The mechanisms by which HIV contributes to CVD are multifaceted and still being investigated. Several factors are believed to play a role:

• Persistent Inflammation: Even with ART, immune activation and inflammation persist in many people with HIV ⁴. This chronic inflammation contributes to the development of atherosclerosis, the buildup of plaque in the arteries.
• Direct Viral Effects: HIV can directly infect heart cells, potentially causing damage, and dysfunction.
• Antiretroviral Therapy (ART) Side Effects: Some ART medications have been linked to increased risk factors for CVD, such as elevated cholesterol levels.
• Traditional Risk Factors: People with HIV may have a higher prevalence of traditional CVD risk factors like high blood pressure, high cholesterol, and diabetes.
• Clonal Hematopoiesis: Recent research suggests that clonal hematopoiesis, a condition involving mutations in blood cells, may contribute to chronic inflammation and ASCVD in people with HIV ⁴.
• Trained Immunity: The concept of “trained immunity,” where immune cells retain a memory of past encounters, may also play a role in persistent inflammation ⁴.

Types of Cardiovascular Disease Associated with HIV

Several types of CVD are more common in people living with HIV:

• Cardiomyopathy: Weakening of the heart muscle.
• Coronary Artery Disease: Narrowing of the arteries that supply blood to the heart.
• Heart Failure: The heart’s inability to pump enough blood to meet the body’s needs.
• Atherosclerotic Cardiovascular Disease (ASCVD): A buildup of plaques in the arteries.
• Ventricular Dysfunction: Impaired ability of the heart’s ventricles to contract and relax properly.

Diagnosis and Monitoring

Advances in cardiac imaging modalities are improving the detection and diagnosis of HIV-associated CVD ². Regular cardiovascular screening is crucial for people living with HIV, including monitoring blood pressure, cholesterol levels, and other risk factors. Diagnostic tools may include:

• Electrocardiogram (ECG)
• Echocardiogram
• Cardiac MRI
• Stress tests

Treatment and Management

Management of CVD in people with HIV involves a combination of strategies:

• Antiretroviral Therapy: Maintaining viral suppression with ART is essential.
• Lifestyle Modifications: Adopting a heart-healthy lifestyle, including a balanced diet, regular exercise, and smoking cessation.
• Medications: Treating high blood pressure, high cholesterol, and other risk factors with appropriate medications.
• Cardiac Rehabilitation: A supervised program to help improve heart health.

Future Research Directions

Further research is needed to fully understand the complex interactions between HIV and CVD. Key areas of focus include:

• Investigating the long-term effects of ART on cardiovascular health.
• Identifying novel biomarkers for early detection of CVD in people with HIV.
• Developing targeted therapies to reduce inflammation and prevent CVD progression.
• Understanding the specific impact of HIV on the cardiovascular system in populations from high-endemic regions, such as sub-Saharan Africa ³.

As people with HIV live longer, proactive cardiovascular care will become increasingly important. A collaborative approach involving infectious disease specialists, cardiologists, and primary care physicians is essential to optimize the health and well-being of this population.